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Abstract 
BACKGROUND: Eosinophilic fasciitis is a rare fibrosing disorder of muscle fascia with rapid onset of erythema, 
induration, oedema and tenderness affecting extremities bilaterally. 
CASE REPORT: We report three cases of eosinophilic fasciitis in 3 females aged 64, 65 and 73 years, in two of 
them in association with morphea. They fulfilled the proposed diagnostic criteria. Associated malignancies could 
be excluded in all of them. They were treated by systemic corticosteroids. In the two females with associated 
morphea higher prednisolone dosages and a combination with methotrexate was necessary. 
CONCLUSIONS: Eosinophilic fasciitis is a differential diagnosis of systemic scleroderma. Response to treatment 
is often delayed. Systemic corticosteroids are the first line therapy. Patients with associated morphea need 
combined drug therapy, in our patients with methotrexate. There is no close correlation between laboratory signs 
of inflammation and clinical response to treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Eosinophilic dermatosis was described first by 
Shulman in 1975 as diffuse fasciitis with 
hypergammaglobulinemia and eosinophilia [1], [2]. 
The disease is now also known as Shulman 
syndrome. It is characterised by abrupt onset with 
bilateral oedema on the limbs, peau d’orange 
appearance of the skin, linear depression along the 
veins (groove sign), and tenderness.  
The induration is progressive and may lead to 
joint contractures in about 50% of patients [3]. In 
Caucasians, women are affected twice as often as 
men, in Japan, the male to female ratio is 1.5:1 [4]. In 
about 25% of cases, only the lower legs are involved, 
but most often all four limbs become affected. 
Raynaud’s phenomenon is typically absent [5]. 
Although cases with trunk involvement have been 
reported, the face is always spared [4]. 
The disease is rare with only 63 patients in 
the largest series reported so far [5].  
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Case reports 
 
Case 1: A 65-year-old woman developed 
plaque-like, erythematous induration on all four 
extremities with tenderness since March 2017. She 
reported a feeling of tension on the ankles with limited 
mobility, muscular pain and weakness, and fatigue. 
She had already unintended lost 7 kg of her body 
weight within 3 months.  
Her medical history was positive for diabetes 
mellitus type II (no medications), arterial hypertension, 
hyperlipoproteinemia, and hyperuricemia. She was a 
smoker with 10 cigarettes per day. 
On examination, we observed symmetric 
brownish hyperpigmentation on lower legs and lower 
arms, and the lower trunk. The skin appeared 
thickened, and it was impossible to crease the skin. 
The groove sign was positive on the legs (Figure 1). 
She had no Raynaud’s phenomenon. 
 
Figure 1: Eosinophilic fasciitis in a 65-year-old woman. Positive 
groove sign on her leg 
 
We took a skin biopsy from the lower arm that 
sowed epidermal atrophy and band-like melanin 
pigmentation of the basal layer. Along the border of 
cutis and subcutis, inflammatory infiltrates composed 
of lymphocytes and monocytes were visible. 
A bone marrow biopsy demonstrated 
increased production of eosinophils. 
Molecular cytogenetic diagnostics excluded 
an eosinophilic myeloproliferative malignancy.  
Laboratory findings: Leukocytosis of 14.3 
Gpt/L, erythrocytes 3.6 Tpt/L, eosinophilia of 8%, C-
reactive Protein 67.1 mg/L. 
Imaging: Computerized tomography (CT) 
scan of the trunk remained unremarkable. Esophago-
duodenoscopy: Helicobacter-associated (HP) 
pangastritis. Coloscopy: Benign colon polyps (Biopsy). 
Treatment and course: Initially we suspected 
a malignancy. The pangastritis was eradicated by 
triple therapy of HP gastritis. The clinical findings with 
peripheral eosinophilia confirmed the diagnosis of 
eosinophilic fasciitis. The patients treated initially with 
60 mg prednisolone/d with slow tapering down the 
doses. We started pantoprazole and cholecalciferol 
therapy to protect the stomach and prevent 
osteoporosis. She responded well. 
Case 2: A 64-year-old woman noted a 
progressive and painful thickening of the soft tissue on 
her lower arms and legs. She suffered from diffuse 
pain of muscles and bones. Her medical history was 
remarkable for allergic asthma. She was treated with 
mepolizumab for one year. The treatment was 
withdrawn in March 2018 because of the suspicion of 
drug-related toxicity. She underwent a corrective 
nasal surgery because of nasal stenosis in May 2018. 
She suffered from pollen allergy, glaucoma and liver 
hemangiomas.  
On examination, we observed erythematous 
lesions with livedo reticularis. The subcutaneous soft 
tissue was fibrotic and thickened. On her lower arms, 
plate-like indurations were noted. The affected limbs 
were painful. Peau d’orange appearance of upper legs 
was obvious (Figure 2). Hands and feet remained 
unaffected. There was no Raynaud’s phenomenon. 
We took a skin biopsy that revealed a 
superficial and deep perivascular and interstitial 
dermatitis with the involvement of eosinophils. The 
subcutaneous adipose tissue presented septal 
panniculitis. 
Laboratory findings: C-reactive protein 24 
mg/L, eosinophilia of 32%, lymphocytes 13%, ß2-
microglobulin 4.6 mg/L, interleukin-2-receptor 2,380 
U/mL. Serology for infections remained negative. 
Antinuclear antibodies 1:160. 
Bone-marrow biopsy: Eosinophilia (31.8%), 
lymphocytes 14%. Molecular cytogenetics and FISH – 
no malignancy, no aberrant cell clone in the bone 
marrow.  
Imaging: X-Ray Thorax: Diffuse fibrotic 
pulmonary changes, mild emphysema. Body 
plethysmography: Minor alterations of diffusion. MRI 
Wollina et al. Eosinophilic Fasciitis – Report of Three Cases and Review of the Literature 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci.                                                                                                                                                                                                         3 
 
abdomen: Steatosis hepatitis, liver hemangioma. MRI 
right lower arm: Hyperintense fascial signals. 
Mammography: Involution. No malignancy.  
 
Figure 2: Eosinophilic fasciitis in a 64-year-old woman. Peau 
d’orange sign 
 
Treatment and course: After confirmation of 
the diagnosis of eosinophilic fasciitis by clinical 
finding, MRI and eosinophilia, we started initially with 
100 mg prednisolone/d and 20 mg pantoprazole/d. 
Ten days later, the prednisolone dosage could be 
reduced to 75 mg/d and methotrexate 15 mg per week 
plus 5 mg folate on the following day. Pain 
management was realised using metamizole and 
hydromorphone. Physical therapy with mobilisation 
and manual lymph drainage was initiated. Within 10 
days, the inflammatory parameters normalised. A very 
slow dose of tapering was recommended for 
outpatient treatment. 
In October 2018, the patient returned to the 
hospital with a worsening of her complaints. At that 
time, she received prednisolone 5 mg/d and 
methotrexate 10 mg/week. We repeated tumour 
screening including coloscopy, esophagogastroscopy 
and CT scans from the head and the trunks that 
remained inconspicuous. MRI of the right lower arm 
demonstrated the improvement of her fasciitis. We 
performed a high-dose pulse therapy with 1000 mg 
prednisolone intravenous infusion on 4 consecutive 
days and increased the methotrexate dosage to 15 
mg/week. On the following days, the dosage of 
prednisolone was 100 mg/d and later 75 gm/d. In 
January 2019 we repeated the high-dose pulse 
therapy on 3 consecutive days. We noted an 
improvement of the thickness of the tissue and 
tenderness on the extremities. On the trunk, however, 
she developed symptomless plaque-type morphea.  
Case 3: A 73-year-old woman developed in 
April 2018 multiple circumscribed plaques on her trunk 
diagnosed as morphea. She was treated by a 
combination of 10 mio U penicillin i.v. And psoralen 
plus UVA therapy (PUVA) resulting in complete 
remission. During the following months, she noted 
relapsing oedema on the extremities with subsequent 
thickening, fibrosis and tenderness on lower arms and 
lower legs. Her medical history was positive for 
hypothyroidism and cataract.  
On examination, we observed symmetrical 
plaque-like subcutaneous indurations on lower arms 
and lower legs. There was a peau d’orange 
appearance of her upper legs (Figure 3). Hands and 
feet remained unaffected. She had no Raynaud’s 
phenomenon.  
 
Figure 3: Eosinophilic fasciitis in a 73-year-old woman. Peau 
d’orange sign 
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A skin biopsy revealed some inflammatory 
infiltrate in the reticular dermis. In the deep dermis, it 
was perivascular, periadnexal and interstitial 
composed of mononuclear cells and some 
eosinophils. In the subcutaneous adipose tissue 
septal tissue became enlarged and presented with 
interstitial cellular infiltrates. Some foreign-body 
granulomas were described. Elastic fibres were 
preserved. 
Laboratory findings: Eosinophilia 7.1% and 
lymphopenia 10%. Gamma-globulins were increased 
(21.6%), lactate dehydrogenase (4.24 µkat/L) and C-
reactive protein (7.28 mg/L) were slightly increased. 
Imaging: An MRI of the right lower arm 
demonstrated fibrosis of the proximal ulnar part and 
generalised enhanced signalling of the fascia.  
Treatment and course: After confirmation of 
eosinophilic fasciitis we performed a high-dose 
prednisolone pulse therapy with 1000 mg/ on 4 
consecutive days with protective pantoprazole 
medication. Afterwards, we switched to oral treatment 
with 100 mg prednisolone/d and 15 mg 
methotrexate/week plus 5 mg folate on the other day 
after methotrexate.  
Pain management was realised with 
ibuprofen. She was also treated with physical therapy 
(manual lymph drainage and mobilisation). A control 
MRI disclosed improvement of the fasciitis and nearly 
completes remission of the fibrosis. Tissue hardening 
could be reduced, and pain relief was achieved 
(Figure 4). The prednisolone dosage could further be 
tapered down.  
 
Figure 4: Patient #3 Improvement of soft tissue tenderness (thigh). 
(a) Before treatment. (b) After high-dose prednisolone pulse therapy 
 
 
 
Discussion 
 
Eosinophilic fasciitis is a rare disease of the 
fibrous spectrum but distinct from systemic 
scleroderma. Diagnostic criteria have been proposed 
by different groups of investigators (Table 1 and 2) [6], 
[7]. Patients with eosinophilic fasciitis are often initially 
misdiagnosed leading to delayed treatment. We 
performed skin biopsies to exclude other dermatoses. 
 
Table 1: Diagnostic criteria for eosinophilic fasciitis [6] 
Major criteria  (a) symmetric or asymmetric diffuse or localised swelling, 
induration and thickening of the skin and subcutaneous tissue 
(b) Histology showing fascial thickening with an accumulation 
of lymphocytes and macrophages with or without eosinophils 
 
Minor criteria  (a) Peripheral eosinophilia (> 0.5 x 10
9
/L) 
(b) Hypergammaglobulinemia (> 1.5 g/L) 
(c) Muscular weakness and/or elevated serum aldolase 
(d) Groove sign and/or peau d’orange appearance of skin 
(e) T2-weighted MRI showing hyperintense fascia 
Exclusion criterion Diagnosis of systemic scleroderma 
 
The pathogenesis of eosinophilic fasciitis is 
not completely understood. Autoimmune mechanisms 
have been suggested, but strenuous exercise or 
labour may trigger the onset. Dermal fibroblasts are 
hyperactive overexpressing type I collagen and 
fibronectin [8].  
Table 2: Japanese diagnostic criteria of eosinophilic fasciitis 
[7] 
Major criterion: 
Symmetrical plate-like sclerotic lesions are present on the four limbs. 
However, this condition lacks Raynaud's phenomenon, and systemic sclerosis can be 
excluded. 
 
Minor criteria 1: 
The histology of a skin biopsy that incorporates the fascia shows fibrosis of the 
subcutaneous connective tissue, with thickening of the fascia and cellular infiltration of 
eosinophils and monocytes. 
 
Minor criteria 2: 
Thickening of the fascia is seen using imaging tests such as magnetic resonance 
imaging (MRI). 
 
A definitive diagnosis is made when a patient has the major criterion and one of the minor 
criteria, or the major criterion and two of the minor criteria. 
 
 
Levels of tissue inhibitor of metalloproteinase-
1 (TIMP-1), an inhibitor of the extracellular matrix-
degrading enzyme matrix metalloproteinase-1, are 
also increased, supporting tissue fibrosis [9]. There 
are reports on altered levels of certain interleukins, 
interferon-gamma, transforming growth factor-β1 
mRNA, and TH17+ cells [4], [5]. 
Diagnosis is confirmed by fascial biopsy and 
histopathology demonstrating fascial thickening, 
fibrosis, and lymphocytic infiltrate [6], [7]. Involvement 
of muscles and adipose tissue may also be present. 
Another diagnostic tool is the MRI that shows 
hyperintense fascia on T2-weighted images [10] 
(Table 3). 
Table 3: Findings of our patients with eosinophilic fasciitis 
Criteria Patient 1 Patient 2 Patient 3 
Major criteria    
(a) Clinical findings + + + 
(b) Fascial histology not done not done not done 
Minor criteria     
(a) Eosinophilia + + + 
(b) Hypergammaglobulinemia - - + 
(c) Muscular weakness + + + 
(d) Groove sign and /   + (+) (+) 
or peau d’orange - + + 
(e) MRI hyperintense fascia + + + 
 
Treatment is not standardised. It is known that 
concurrent morphea is associated with a 1.4 to 3 
times higher risk of resistance to systemic 
corticosteroid therapy [8], [11]. Our experience with 
two patients with associated morphea supports this 
finding. Both did not respond to oral corticosteroids 
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and needed a combined medication with methotrexate 
and intravenous high-dose pulse steroids. Medical 
treatment was supported by pain management and 
physical therapy. The latter is of importance to prevent 
joint contractures [5]. Since eosinophilic fasciitis may 
be a facultative paraneoplastic disorder, exclusion of 
underlying malignancies is of importance [3], [4], [5]. 
We performed imaging investigations and bone-
marrow biopsies. In all three of our patients, a 
malignant background could be excluded.  
The course of the disease often needs many 
months to several years of treatment. The keystones 
of drug therapy are systemic corticosteroids and 
methotrexate. Other drugs that have been 
occasionally used are mycophenolate mofetil, 
cyclosporin A, dapsone, azathioprine, tumour necrosis 
factor-inhibitors, sirolimus, immunoglobulins, and D-
penicillamine. Photo(chemo)therapy with either UVA1, 
PUVA or extracorporeal photochemotherapy has also 
been reported [12]. There are some case reports 
about the successful but off-label use of interleukin-6 
antagonist tocilizumab [13], anti-CD-antibody 
rituximab [14], and Janus kinase inhibitor tofacitnib 
[15]. In some of the cases, these new drugs have 
been used in combination with either methotrexate or 
prednisolone. We achieved improvement with 
systemic corticosteroids with or without methotrexate. 
In conclusion, eosinophilic fasciitis is rare but 
probably underdiagnosed. The disease should not be 
mistaken for systemic scleroderma since treatment 
and prognosis are different. Careful clinical 
investigation, histopathology, eosinophilia in 
peripheral blood, and MRI allow the confirmation of 
diagnosis. Keystones of treatment are systemic 
corticosteroids and methotrexate, although other 
compounds have also been used occasionally. 
Physical therapy is essential to prevent joint 
contractures that develop in half of the patients. 
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